Founder of Gen Probe Joins Xenomics Board.

NEW YORK -- Xenomics, Inc. (OTCBB:XNOM) announced today that its Board of Directors appointed Thomas H. Adams, Ph.D. as a director of the Company. Xenomics is a molecular diagnostic company that has developed a proprietary non-invasive technology that uses urine samples instead of blood or tissue

Dr. Adams brings to Xenomics over 35 years of experience in the medical diagnostics industry. He held top management positions with DuPont, Hyland and Technicon and is responsible for developing more than 100 commercial diagnostic products. As Vice President Research and Development and CTO for Hybritech he was instrumental in bringing Prostate Specific Antigen (PSA) to market. Dr. Adams was a co-founder, Chairman and CEO of Gen Probe Inc., a leading developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood. More recently he was founder of Genta, Inc., a pharmaceutical company developing antisense cancer drug therapies. Currently he is founder and CEO of Leucadia Technologies Inc., a private biotechnology company working in the area of ultra-sensitive molecular detection of proteins for the diagnosis of cancer and infectious diseases.

"Dr. Adams has a long and distinguished record of developing cutting edge technology into highly successful commercial products. He is a seasoned executive and we are pleased to welcome him to the Board and look forward to his steady and insightful guidance," said Randy White, Ph.D., the CEO of Xenomics.

Dr. Adams said, "I am excited to join the Board of Directors of Xenomics as the Company transitions from research into product development. I believe that Xenomics' technology will revolutionize molecular diagnostic testing in many fields of molecular medicine."

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using trans-renal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of testing including: prenatal testing; tumor detection and monitoring; tissue transplantation; infectious disease; forensic identity; drug development and bioterrorism. Xenomics believes that its technology will open new molecular markets. Xenomics' scientists were the first to report that a portion of DNA from normal cell death throughout the body not only appears in the bloodstream but crosses the kidney barrier and can be detected in urine. Xenomics has 3 issued patents covering different applications of the technology for molecular diagnostics and genetic testing. Xenomics has organized a joint venture to conduct research on infectious disease detection with the Spallanzani National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive) in Rome, Italy, in the form of a new R&D company called SpaXen Italia, S.R.L.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing.